about
Glypican-3 Targeting Immunotoxins for the Treatment of Liver CancerTargeting Strategies for Renal Cell Carcinoma: From Renal Cancer Cells to Renal Cancer Stem CellsExperimental procedures to identify and validate specific mRNA targets of miRNAsEndoglin promotes angiogenesis in cell- and animal-based models of retinal neovascularization.Gene Electrotransfer of Plasmid with Tissue Specific Promoter Encoding shRNA against Endoglin Exerts Antitumor Efficacy against Murine TS/A Tumors by Vascular Targeted Effects.Tumor neoangiogenesis detection by confocal laser endomicroscopy and anti-CD105 antibody: Pilot study.miR-342-5p Is a Notch Downstream Molecule and Regulates Multiple Angiogenic Pathways Including Notch, Vascular Endothelial Growth Factor and Transforming Growth Factor β Signaling.An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer.A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenibElectrotransfer of Plasmid DNA Encoding an Anti-Mouse Endoglin (CD105) shRNA to B16 Melanoma Tumors with Low and High Metastatic Potential Results in Pronounced Anti-Tumor Effects.Cancer prevention and therapy through the modulation of the tumor microenvironment.The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review.Endoglin-based biological therapy in the treatment of angiogenesis-dependent pathologies.Detailed assessment of microvasculature markers in non-small cell lung cancer reveals potentially clinically relevant characteristics.Anti-Human Endoglin (hCD105) Immunotoxin-Containing Recombinant Single Chain Ribosome-Inactivating Protein Musarmin 1.Tumor radiosensitization by gene therapy against endoglin.Endoglin and alk1 as therapeutic targets for hereditary hemorrhagic telangiectasia.M1-like macrophages change tumor blood vessels and microenvironment in murine melanoma.Prognostic value of endoglin-assessed microvessel density in cancer patients: a systematic review and meta-analysis.Assessing Tumor Angiogenesis in Histological Samples.In Vivo Tumor-Targeted Dual-Modality PET/Optical Imaging with a Yolk/Shell-Structured Silica NanosystemSoluble endoglin regulates expression of angiogenesis-related proteins and induction of arteriovenous malformations in a mouse model of hereditary hemorrhagic telangiectasia
P2860
Q28077270-12F078CC-B347-4368-9190-9A5840D83F32Q28078154-F409FD98-C7E4-4A40-9AAC-B88B07170FAFQ28087216-89713BB5-37D9-4463-B342-12832CAD1A85Q34341837-3925159C-5FB8-47C4-951C-52F00EFCA92EQ35536671-DB50CA53-9139-4E6D-971F-39152FFD949CQ35851032-4A6B4E50-98EF-49EF-9DD8-5257F5785FCFQ35917632-7DC290C7-E8C4-4CE0-8A44-DA24AB10354FQ36061812-670D3562-7E6D-4812-8F8F-8DB43D360245Q36223538-9E2E4EA2-6058-4897-A690-0EA82952A9D2Q36506981-DBFD165C-06DF-4270-A264-5DB7E44E5D75Q37058267-351AAB93-567E-4814-9DE7-758FE64C787EQ38910154-C2FADE6A-6773-4A6A-AA21-8E058B4303A7Q39401943-3B630EB9-DEC8-4CC4-B084-C836800BB00EQ41099763-524D5C5B-CDC1-4C6E-80E6-D4BD2FCB460CQ42253064-7838E750-AA38-4F45-BBAB-108763322F25Q45886138-80004086-C35E-4B68-BD14-E9B95A3645E1Q47968783-D1002082-6503-4F48-BC30-74D8818463A5Q48269732-BC5FFF5E-38BD-4DC5-A6EA-40A3FE7282A9Q50358087-B737504F-DFF4-45E8-9659-97D2C02D1453Q51525609-B16DD98E-6605-46D4-81A0-5C91659ADAA2Q58582293-710326DD-2F19-4A4C-86A9-C63AF8B3D86EQ58703191-2A234C82-5F1B-4CC6-AACE-055D7DCA01ED
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Endoglin for targeted cancer treatment.
@en
type
label
Endoglin for targeted cancer treatment.
@en
prefLabel
Endoglin for targeted cancer treatment.
@en
P2093
P2860
P1476
Endoglin for targeted cancer treatment.
@en
P2093
Francisco Robert
Lee S Rosen
Michael S Gordon
P2860
P2888
P356
10.1007/S11912-013-0365-X
P577
2014-02-01T00:00:00Z
P6179
1023480768